Rasio utang jangka dawa marang modal Editas Corp (EDIT)

Editas Medicine, Inc. (EDIT) specializes in developing innovative genetic drugs. Its operations are constrained by strict ethical oversight and complexities associated with bringing products to market. Business revenues rely on licensing payments and genome editing partnership agreements, with the indicator standing at 0.57. This price chart reflects the impact of current contracts and the development prospects of its proprietary therapy programs.

This ratio determines the extent of the company's dependence on long-term credit obligations relative to its equity, measuring financial stability and default risk. An analysis of the long-term debt-to-equity ratio demonstrates the financing structure of Editas Medicine, Inc. (EDIT), where the absence of debt confirms a strategic focus on the monetization of intellectual property and partnership licenses rather than external loans.